Literature DB >> 20962274

Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo.

Elizabeth A Slee1, Barbara Benassi, Robert Goldin, Shan Zhong, Indrika Ratnayaka, Giovanni Blandino, Xin Lu.   

Abstract

The tumor suppressor p53 is a master sensor of stress, and posttranslational modifications are key in controlling its stability and transcriptional activities. p53 can be phosphorylated on at least 23 Ser/Thr residues, the majority of which are phosphorylated by stress-related kinases. An exception is Ser315 in human p53 (Ser312 in mouse), which is predominantly phosphorylated by cell cycle-related kinases. To understand the biological importance of Ser312 phosphorylation in vivo, we generated p53Ser312Ala knock-in mice. We show here that, although Ser312 is not essential for mouse life span under normal physiological conditions, Ser312Ala mutation dampens p53's activity during embryonic development. This is evident from its partial rescue of embryonic lethality caused by Mdm4 deletion. In agreement with the notion that Ser312 mutation weakens p53 function, Ser312Ala mice are also more susceptible to tumorigenesis following a sublethal ionizing radiation dose. Importantly, in the cohort studied, Ser312 mutation predisposes mice to develop thymic lymphomas and liver tumors, partly due to p53Ser312Ala's inability to fully induce a set of p53 target genes including p21 and cyclin G1. Thus, we demonstrate that phosphorylation of Ser312 is required for p53 to function fully as a tumor suppressor in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962274      PMCID: PMC2984175          DOI: 10.1073/pnas.1005165107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription.

Authors:  J P Blaydes; M G Luciani; S Pospisilova; H M Ball; B Vojtesek; T R Hupp
Journal:  J Biol Chem       Date:  2000-11-14       Impact factor: 5.157

2.  mdmx is a negative regulator of p53 activity in vivo.

Authors:  Rick A Finch; Dorit B Donoviel; David Potter; Min Shi; Amy Fan; Deon D Freed; Ching-Yun Wang; Brian P Zambrowicz; Ramiro Ramirez-Solis; Arthur T Sands; Nan Zhang
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

3.  The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response.

Authors:  Hongwu Zheng; Han You; Xiao Zhen Zhou; Stephen A Murray; Takafumi Uchida; Gerburg Wulf; Ling Gu; Xiaoren Tang; Kun Ping Lu; Zhi-Xiong Jim Xiao
Journal:  Nature       Date:  2002-10-02       Impact factor: 49.962

4.  Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases.

Authors:  Y Wang; C Prives
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

5.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

Authors:  C Kuperwasser; G D Hurlbut; F S Kittrell; E S Dickinson; R Laucirica; D Medina; S P Naber; D J Jerry
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

6.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.

Authors:  J Parant; A Chavez-Reyes; N A Little; W Yan; V Reinke; A G Jochemsen; G Lozano
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

7.  Tumor susceptibility of p21(Waf1/Cip1)-deficient mice.

Authors:  J Martín-Caballero; J M Flores; P García-Palencia; M Serrano
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

8.  Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.

Authors:  Domenico Migliorini; Eros Lazzerini Denchi; Davide Danovi; Aart Jochemsen; Manuela Capillo; Alberto Gobbi; Kristian Helin; Pier Giuseppe Pelicci; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

9.  Changes in transcriptome after in vivo exposure to ionising radiation reveal a highly specialised liver response.

Authors:  Alexandre Pawlik; Paul Delmar; Sebastien Bosse; Laurie Sainz; Cyrille Petat; Genevieve Pietu; Dominique Thierry; Diana Tronik-Le Roux
Journal:  Int J Radiat Biol       Date:  2009-08       Impact factor: 2.694

10.  Reduced p21(WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas.

Authors:  Y Z Shi; A M Hui; T Takayama; X Li; X Cui; M Makuuchi
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

View more
  9 in total

Review 1.  Illuminating p53 function in cancer with genetically engineered mouse models.

Authors:  Patty B Garcia; Laura D Attardi
Journal:  Semin Cell Dev Biol       Date:  2014-01-03       Impact factor: 7.727

Review 2.  Mutant TP53 posttranslational modifications: challenges and opportunities.

Authors:  Thuy-Ai Nguyen; Daniel Menendez; Michael A Resnick; Carl W Anderson
Journal:  Hum Mutat       Date:  2014-02-11       Impact factor: 4.878

3.  A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity.

Authors:  Sylwia Kabacik; Ana Ortega-Molina; Alejo Efeyan; Paul Finnon; Simon Bouffler; Manuel Serrano; Christophe Badie
Journal:  Cell Cycle       Date:  2011-04-01       Impact factor: 4.534

4.  Transcriptional and translational regulation of C/EBPβ-HDAC1 protein complexes controls different levels of p53, SIRT1, and PGC1α proteins at the early and late stages of liver cancer.

Authors:  Jingling Jin; Polina Iakova; Yanjun Jiang; Kyle Lewis; Emily Sullivan; Nicole Jawanmardi; Lawrence Donehower; Lubov Timchenko; Nikolai A Timchenko
Journal:  J Biol Chem       Date:  2013-04-05       Impact factor: 5.157

5.  Small changes huge impact: the role of protein posttranslational modifications in cellular homeostasis and disease.

Authors:  Tejaswita M Karve; Amrita K Cheema
Journal:  J Amino Acids       Date:  2011-07-21

6.  Requirement for phosphorylation of P53 at Ser312 in suppression of chemical carcinogenesis.

Authors:  Elizabeth A Slee; Xin Lu
Journal:  Sci Rep       Date:  2013-10-31       Impact factor: 4.379

Review 7.  Exploiting unique structural and functional properties of malarial glycolytic enzymes for antimalarial drug development.

Authors:  Asrar Alam; Md Kausar Neyaz; Syed Ikramul Hasan
Journal:  Malar Res Treat       Date:  2014-12-17

Review 8.  Tumor suppressive role for kinases phosphorylating p53 in DNA damage-induced apoptosis.

Authors:  Satomi Yogosawa; Kiyotsugu Yoshida
Journal:  Cancer Sci       Date:  2018-10-06       Impact factor: 6.716

9.  Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.

Authors:  Oleg Timofeev; Boris Klimovich; Jean Schneikert; Michael Wanzel; Evangelos Pavlakis; Julia Noll; Samet Mutlu; Sabrina Elmshäuser; Andrea Nist; Marco Mernberger; Boris Lamp; Ulrich Wenig; Alexander Brobeil; Stefan Gattenlöhner; Kernt Köhler; Thorsten Stiewe
Journal:  EMBO J       Date:  2019-09-04       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.